Deal worth $156m to provide HIV drugs for Africa
The Global Fund to Fight AIDS, tuberculosis and malaria has signed a $156 million grant agreement with Zambia that aims to ensure a secure supply of antiretroviral (ARV) medicine to all those receiving HIV treatment.
The new funding will also support work that gets 225,000 more people to start treatment over the next three years. Some 480,000 people in Zambia are enrolled on antiretroviral treatment with Global Fund support.
Joseph Kasonde, Minister of Health, Republic of Zambia, said: “Continued support from the Global Fund allows us to increase HIV testing and start thousands more people on treatment. It will also allow us to pursue the elimination of mother-to-child transmission of HIV and to increase coverage of male circumcision.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze